HomeCompareBZQIF vs JNJ

BZQIF vs JNJ: Dividend Comparison 2026

BZQIF yields 4.00% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 JNJ wins by $4.3K in total portfolio value· pulled ahead in Year 9
10 years
BZQIF
BZQIF
● Live price
4.00%
Share price
$2.55
Annual div
$0.10
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$25.9K
Annual income
$517.30
Full BZQIF calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — BZQIF vs JNJ

📍 JNJ pulled ahead of the other in Year 9

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBZQIFJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BZQIF + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BZQIF pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BZQIF
Annual income on $10K today (after 15% tax)
$340.10/yr
After 10yr DRIP, annual income (after tax)
$439.70/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, JNJ beats the other by $3,546.29/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BZQIF + JNJ for your $10,000?

BZQIF: 50%JNJ: 50%
100% JNJ50/50100% BZQIF
Portfolio after 10yr
$28.1K
Annual income
$2,603.35/yr
Blended yield
9.26%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

BZQIF
Analyst Ratings
1
Hold
Consensus: Hold
Altman Z
1.9
Piotroski
7/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BZQIF buys
0
JNJ buys
8
PoliticianChamberTickerTypeAmountDate
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002026-01-23
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-12-18
Lloyd Doggett🏢 House$JNJ▲ Buy$1,001 - $15,0002025-12-09
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002025-11-20
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-11-13
Rich McCormick🏢 House$JNJ▲ Buy$1,001 - $15,0002025-11-05
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Jared Moskowitz🏢 House$JNJ▼ Sell$1,001 - $15,0002025-10-10
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBZQIFJNJ
Forward yield4.00%2.13%
Annual dividend / share$0.10$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%28%
Portfolio after 10y$25.9K$30.3K
Annual income after 10y$517.30$4,689.40
Total dividends collected$4.6K$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusHoldBuy

Year-by-year: BZQIF vs JNJ ($10,000, DRIP)

YearBZQIF PortfolioBZQIF Income/yrJNJ PortfolioJNJ Income/yrGap
1$11,100$400.12$10,592$272.30+$508.00BZQIF
2$12,292$415.08$11,289$357.73+$1.0KBZQIF
3$13,582$429.59$12,123$472.89+$1.5KBZQIF
4$14,977$443.62$13,141$629.86+$1.8KBZQIF
5$16,482$457.16$14,408$846.81+$2.1KBZQIF
6$18,106$470.20$16,021$1,151.60+$2.1KBZQIF
7$19,856$482.74$18,122$1,588.22+$1.7KBZQIF
8$21,741$494.76$20,930$2,228.20+$811.00BZQIF
9← crossover$23,769$506.29$24,792$3,191.91$1.0KJNJ
10$25,950$517.30$30,274$4,689.40$4.3KJNJ

BZQIF vs JNJ: Complete Analysis 2026

BZQIFStock

Bezeq The Israel Telecommunication Corporation Limited provides communications services to business and private customers in Israel. It operates in four segments: Fixed-line Domestic Communication; Cellular Communication; Internet, International Communications, and NEP Services and ICT Solutions; and Multi-channel Television. The company offers telephony services, including basic telephony services on the domestic telephone line, as well as associated services, such as voice mail and caller ID; national numbering services; broadband Internet access infrastructure services; and transmission and data-communication services. It also provides virtual server services; Bcyber services; smart business services; private virtual PBX services; and B144 service, an advertising platform for digital advertising and marketing to small businesses, BCam, Wi-Fi, SMS, and remote backup. In addition, the company offers infrastructure services, company's network connection, billing services, and space leasing; and operates and maintains radio transmitters for broadcasting of radio and television contents. Further, it provides basic telephone, browsing and data communications, messaging, push to talk, Internet of Things, roaming, and servicing and repair services, as well as sells terminal equipment; installs, operates, and maintains cellular communication equipment and systems; and offers infrastructure and communication technologies solutions, as well as data transmission, NEP, PBX, multi-channel digital satellite television, over the Internet and value added services. The company was founded in 1980 and is based in Holon, Israel.

Full BZQIF Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this BZQIF vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BZQIF vs SCHDBZQIF vs JEPIBZQIF vs OBZQIF vs KOBZQIF vs MAINBZQIF vs ABBVBZQIF vs MRKBZQIF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.